AstraZeneca acquires a Chinese cancer drug developer with a transaction value of approximately $1.2 billion
白云追月素
发表于 2023-12-26 20:35:32
286
0
0
AstraZeneca announced on Tuesday local time that a final agreement has been signed on the proposed acquisition of Gracell, which will add GC012F CAR-T cell therapy to AstraZeneca's expanding cell therapy pipeline.
CandyLake.com is an information publishing platform and only provides information storage space services.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
转播
You may like
- Yum China announces share buyback plan involving approximately $360 million
- Yum China announces plans to repurchase approximately $360 million worth of shares
- General Motors China responds to rumors of 'General Motors plans to restructure its business in China'
- Starbucks' '' China Anxiety '
- The three major indexes of the US stock market collectively closed down, while the Nasdaq China Golden Dragon Index rose more than 8% and tripled. Go long, FTSE China ETF rose nearly 24%
- Global market: Chinese assets explode, China Golden Dragon Index rises 8.54%, 3-fold long, FTSE China ETF rises nearly 24%
- China's US Treasury holdings hit the lowest level in over 15 years in October! Is the wave of US debt reduction spreading globally?
- What is the impact of the Biden administration's 301 investigation on China's mature process chip industry?
- Lilly weight loss pills are now available for purchase on e-commerce platforms. Lilly China responds that they are self funded drugs
- Chinese assets suddenly exploded! Multiple Chinese concept stocks rose by over 10%
